Samsung Biologics to engage with global pharma at BIO-Europe and World ADC
Samsung Biologics will participate in two major conferences this November and engage with global biopharma partners to meet their development and manufacturing needs.
At BIO-Europe, which takes place November 3–6, Samsung Biologics will connect with existing and potential clients at Booth #C19 while highlighting its end-to-end, integrated CDMO services.
At World ADC San Diego, which takes place November 4–6, Samsung Biologics will showcase its antibody-drug conjugate (ADC) development and manufacturing capabilities. Marc Studer, Head of ADC & mRNA Operations, will deliver a session on “Overcoming the Challenges in Residual Payloads: Cleaning and Analytical Strategies,” outlining methods for product safety and facility cleanliness. Jaeook Kim, Lead Scientist of ADC Non-GMP Analytics, will present a poster on “Analytical Method Development Strategies for ADC Molecules on Expedited Timelines.” The company will also meet with clients and partners at Table-top Booth #39.
Through these engagements, Samsung Biologics aims to align with diverse client needs, offer tailored services, and explore new collaboration opportunities.
Samsung Biologics will participate in two major conferences this November and engage with global biopharma partners to meet their development and manufacturing needs.
At BIO-Europe, which takes place November 3–6, Samsung Biologics will connect with existing and potential clients at Booth #C19 while highlighting its end-to-end, integrated CDMO services.
At World ADC San Diego, which takes place November 4–6, Samsung Biologics will showcase its antibody-drug conjugate (ADC) development and manufacturing capabilities. Marc Studer, Head of ADC & mRNA Operations, will deliver a session on “Overcoming the Challenges in Residual Payloads: Cleaning and Analytical Strategies,” outlining methods for product safety and facility cleanliness. Jaeook Kim, Lead Scientist of ADC Non-GMP Analytics, will present a poster on “Analytical Method Development Strategies for ADC Molecules on Expedited Timelines.” The company will also meet with clients and partners at Table-top Booth #39.
Through these engagements, Samsung Biologics aims to align with diverse client needs, offer tailored services, and explore new collaboration opportunities.
Share article
Related Content